You may hear this called Philadelphia positive leukaemia. Dasatinib is a type cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking a signal that tells leukaemia cells to grow ...

Researchers discovered that COVID-19 and chronic hepatitis B share key genetic pathways related to the immune system. This ...

A quarter century of groundbreaking research has transformed the landscape for treating Philadelphia chromosome–positive leukemia.

Aurobindo’s wholly owned subsidiary, Eugia Pharma Specialities, has received the Food and Drug Administration’s permission to manufacture and market dasatinib tablets, in dosage strengths of 20 mg, 50 ...

Aurobindo Pharma subsidiary Eugia Pharma Specialities has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Dasatinib Tablets in different ...

Eugia Pharma, part of Aurobindo, wins USFDA approval for Dasatinib Tablets. Tablets bioequivalent to Sprycel, available in multiple dosages. Launch set for fiscal year 2026, targeting US$ 1.8 ...

Aurobindo Pharma made an announcement stating that its fully-owned subsidiary, Eugia Pharma Specialities Limited, has got final USFDA approval to make and sell Dasatinib Tablets in the US.

Zydus Lifesciences Ltd has bagged final approval from the US Food and Drug Administration (USFDA) to produce and market Dasatinib tablets in the US. The approved strengths are 20 mg, 50 mg ...

Zydus Lifesciences share price gained more than 3 percent in the early trade on March 6 after the company received final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg ...

PHYRAGO™ is the first and only dasatinib product that can be co-administered with gastric acid-reducing agents. An estimated one-third of patients who require SPRYCEL ® treatment may also take gastric ...

PHYRAGO™ is the first and only dasatinib product that can be co-administered with gastric acid-reducing agents. An estimated one-third of patients who require SPRYCEL ® treatment may also take ...

"PHYRAGO™ represents a novel dasatinib formulation that delivers equivalent efficacy to SPRYCEL ®, with the additional benefit of allowing patients to take dasatinib with gastric acid-reducing agents" ...